49 results about "Agonist substance" patented technology

Disclosed are compounds of Formula (I)or pharmaceutically acceptable salts thereof, whereinQ isR1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, —OR4, and / or halogen;and R2, R3, R4, and n are defined herein.Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The invention relates to indole derivative having the general Formula Iwherein A represents a 5-membered aromatic heterocyclic ring, wherein X1, X2 and X3 are independently selected from N, O, S and CH; Y represents CH2, O, S or SO2; R1 is H, (C1-4)-alkyl, (C1-4)alkyloxy, CN or halogen; R2, R2′, R3, R3′, R4, R4′, R5 and R5′ are independently hydrogen, (C1-4)alkyl (optionally substituted with OH) or CO—OR8; or one pair of geminal substituents R3 and R3′ or R5 and R5′ together represent a keto group, and the others are all hydrogen or (C1-4)alkyl; or R2 and R5 together represent a methylene or an ethylene bridge, and R2′, R3, R3′, R4, R4′ and R5′ are hydrogen; n is 1 or 2; R6 is H, (C1-4)alkyl (optionally substituted with OH, (C1-4)alkyloxy, CO—NR9R10, CO—OR11 or 1,2,4-oxadiazol-3-yl), SO2NR12R13 or COOR14; R7 is H or halogen; R8 is (C1-4)alkyl; R9 and R10 are independently hydrogen, (C1-4)alkyl or (C3-7)cycloalkyl, the alkyl groups being optionally substituted with OH or (C1-4)alkyloxy; R11 is H or (C1-4)alkyl; R12 and R13 are independently H or (C1-4)alkyl; R14 is (C1-6)alkyl; or a pharmaceutically acceptable salt thereof, as agonists of the cannabinoid CB1 receptor, which can be used in the treatment of pain such as for example peri-operative pain, chronic pain, neuropathic pain, cancer pain and pain and spasticity associated with multiple sclerosis.

A freeze-dried powder injection of fenoldopam methylsulfonate as the D1-type dopamine receptor excitomotor is prepared from fenoldopam methylsulfonate, the pharmacologically acceptable acidic substance through preparing clear solution and freeze drying.

Material and method for using 4-1BB agonizes to treat or prevent autoimmune disorders, lymphoproliferative diseases, and allergies are provided.

The invention provides a liquid chromatography-mass spectrometry method for rapidly detecting the content of beta-agonists. The liquid chromatography-mass spectrometry method comprises the following steps: pretreating a sample, namely, sequentially adding water and an organic extracting solution in the sample for extracting a beta-receptor stimulant; then adding a salting-out agent and a water removing agent to ensure that the organic extracting solution and a water phase demix, centrifuging to obtain a first supernate, adding an adsorbing agent in the first supernate for purification, centrifuging to obtain a second supernate, concentrating, re-dissolving and filtering the second supernate to prepare a sample to be detected; and then detecting the beta-receptor stimulant contained in an animal-derived food by adopting an ultra-high performance liquid chromatography-triple quadrupole mass spectrometer. According to the sample pretreatment method suitable for liquid chromatography-mass spectrometry detection, provided by the invention, interfering molecules are removed through extraction and purification so that high accuracy is achieved in sample detection.